What happened
Boltz, an AI drug discovery startup headquartered in London, has closed a $110m Series A round led by Bessemer Venture Partners, Tech.eu reported. The raise comes less than a year after the company came out of stealth and follows a $28m seed round it secured at the start of the year. Returning backers also took part, among them Obvious Ventures, Zetta Venture Partners, Amplify Partners and Andreessen Horowitz.
Greycroft, F-Prime Capital, Hummingbird and Benchling joined as new investors. They sit alongside Nvidia, whose investment in Boltz was announced earlier this year while Jensen Huang was visiting the UK. The company said it plans to put the new capital into compute and data and into growing its team, which currently counts 40 AI researchers working in the King's Cross area of London.
Boltz said it believes model capabilities are only at the start of an exponential climb, and that its next models already generate noticeably better molecules. Its stated long-term aim is to let a scientist move from a therapeutic idea to a molecule ready for human use without leaving the computer, a goal the company said will require further model advances and heavy spending on compute and data.
Context
Boltz began at MIT, where its co-founders put out freely available models whose performance matched closed systems such as DeepMind's AlphaFold3. Those models are now a default choice in early-stage drug discovery. Its software predicts how proteins and drug candidates fit together, estimates binding strength and designs new molecules for a target. Its named collaborators include Bristol Myers Squibb, Takeda, GSK and Pfizer.
Le briefing
La semaine tech, en un seul e-mail.
Les dépêches qui méritent votre temps, chaque semaine. Désinscription à tout moment.
